B

BMC Medical Co Ltd
SZSE:301367

Watchlist Manager
BMC Medical Co Ltd
SZSE:301367
Watchlist
Price: 67.98 CNY 0.67% Market Closed
Market Cap: 6.1B CNY
Have any thoughts about
BMC Medical Co Ltd?
Write Note

BMC Medical Co Ltd
Net Issuance of Common Stock

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

BMC Medical Co Ltd
Net Issuance of Common Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Common Stock CAGR 3Y CAGR 5Y CAGR 10Y
B
BMC Medical Co Ltd
SZSE:301367
Net Issuance of Common Stock
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
A
APT Medical Inc
SSE:688617
Net Issuance of Common Stock
ÂĄ34.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
J
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SZSE:002223
Net Issuance of Common Stock
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
Net Issuance of Common Stock
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
J
Jafron Biomedical Co Ltd
SZSE:300529
Net Issuance of Common Stock
ÂĄ0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Shanghai United Imaging Healthcare Co Ltd
SSE:688271
Net Issuance of Common Stock
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

BMC Medical Co Ltd
Glance View

Market Cap
6.1B CNY
Industry
Health Care

BMC Medical Co. Ltd. principally engages in the research, development, production, and sale of medical equipment and consumable products in the field of respiratory health. The company is headquartered in Beijing, Beijing and currently employs 843 full-time employees. The company went IPO on 2022-11-01. The firm's products mainly include non-invasive home ventilators, ventilation masks, sleep monitors and high-flow humidified oxygen therapy devices. The firm also provides respiratory health chronic disease management services. The firm focuses on the treatment of patients with sleep apnea-hypopnea syndrome (SAHS), mainly obstructive sleep apnea syndrome (OSA), as well as patients with respiratory insufficiency, mainly chronic obstructive pulmonary disease (COPD), providing a full-cycle and multi-scenario overall solution for treatment services.

Intrinsic Value
63.07 CNY
Overvaluation 7%
Intrinsic Value
Price
B

See Also

Back to Top